Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
RESEARCH TOOLSreports
Holding BMRN?
Track your performance easily
BMRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$68.83 - $99.56
Previous Close$71.14
Volume1.21M
Average Volume (3M)2.21M
Market Cap
$13.56B
Enterprise Value$13.41B
Total Cash (Recent Filing)$1.22B
Total Debt (Recent Filing)$1.09B
Price to Earnings (P/E)53.7
Beta0.62
Next Earnings
Oct 23, 2024EPS Estimate
$0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.32
Shares Outstanding190,382,822
10 Day Avg. Volume2,923,130
30 Day Avg. Volume2,211,724
Standard Deviation0.09
R-Squared0.03
Alpha0.00343
Financial Highlights & Ratios
Price to Book (P/B)2.56
Price to Sales (P/S)5.19
Price to Cash Flow (P/CF)28.30
P/FCF Ratio34.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.18
Enterprise Value/Gross Profit7.04
Enterprise Value/Ebitda32.09
Forecast
1Y Price Target
$105.52Price Target Upside48.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
BioMarin Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
First-Mover AdvantageVoxzogo's first mover advantage and head start in infants.
Market OpportunityThe market opportunity addressable by Voxzogo/Transcon-CNP is substantial (~$5B).
Stock ValuationShares look meaningfully undervalued, not reflecting market growth from new indications that can offset competitive pressures.
Bears Say
Commercial UptakeSlow Valrox commercial uptake is expected due to its variable effect, frequent follow-up exams, and effective standard of care.
Competitor AdvantageTransCon CNP’s once-weekly dosing and better efficacy on height could allow it to surpass Voxzogo in market share.
Market ShareNew competitors are projected to reduce Voxzogo's US market share in achondroplasia significantly over time.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $68.83 and its highest was $99.56 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
Currently, no data Available
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Oct 23, 2024 which is in 34 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Aug 05, 2024. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.358 by $0.192.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is $0.53.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 190,382,830 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $0.55 in its last earnings report, beating expectations of $0.358. Following the earnings report the stock price went up 7.953%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Among the largest hedge funds holding BioMarin Pharmaceutical’s share is PRIMECAP Management Co. It holds BioMarin Pharmaceutical’s shares valued at 2B.
---
BioMarin Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$105.52 (48.12% Upside)
$105.52 (48.12% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.2%
Last 30 Days ▲ 16.9%
Last 30 Days ▲ 16.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.70%
12-Months-Change
Fundamentals
Return on Equity
5.10%
Trailing 12-Months
Asset Growth
7.68%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
---
BMRN Company Deck
---
BMRN Earnings Call
Q2 2024
0:00 / 0:00
---
BMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BMRN Stock 12 Month Forecast
Average Price Target
$105.52
▲(48.12% Upside)
Technical Analysis
Best Analysts Covering BMRN
1 Year
1 Year Success Rate
24/47 ratings generated profit
1 Year Average Return
-1.46%
reiterated a buy rating 3 days ago
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 51.06% of your transactions generating a profit, with an average return of -1.46% per trade.
---